Evenity (Romosozumab) Year-1 Outcomes: What Real Users Actually Experience

What the Clinical Trials Actually Show at 12 Months

The phase 3 FRAME trial enrolled 7,180 postmenopausal women with osteoporosis and randomized them to romosozumab 210 mg SC monthly or placebo for 12 months. At the 12-month mark, lumbar spine BMD increased by 13.3% in the romosozumab group versus 0% in the placebo group (P<0.001). [1] New vertebral fractures occurred in 0.5% of the romosozumab group versus 1.8% placebo, a 73% relative risk reduction. [1]

The ARCH trial (N=4,093) compared romosozumab head-to-head against alendronate 70 mg weekly for 12 months in women with a prior vertebral fracture. Romosozumab produced a 48% lower rate of new vertebral fractures compared with alendronate at 24 months when followed by alendronate in both arms. [2]

Bone Density by Site

Gains are not uniform across skeletal sites. FRAME reported:

• Lumbar spine: +13.3% at 12 months [1]
• Total hip: +6.9% at 12 months [1]
• Femoral neck: +5.9% at 12 months [1]

These numbers matter clinically because hip fracture carries roughly a 20-to-24% one-year mortality rate in older adults. [3] Faster hip BMD gains may translate to earlier fracture protection compared with bisphosphonates, which typically produce 2-to-4% hip BMD increases over the same period. [4]

How Romosozumab Works Differently

Romosozumab inhibits sclerostin, a glycoprotein secreted by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab increases bone formation markers (P1NP rises sharply in months 1-3) while transiently decreasing bone resorption markers (CTX). [5] This dual mechanism is absent in bisphosphonates or denosumab, which work only on the resorption side.

The bone-formation signal fades after roughly 9-12 months of continuous dosing, which is why the regimen is capped at 12 injections and must be followed immediately by an antiresorptive agent to preserve the gains. [6]

Real User Reports: Reddit and Patient Forums

Patient-reported experience on Reddit (r/osteoporosis, r/TwoXChromosomes) and Drugs.com largely aligns with trial outcomes, though the emotional tone is more nuanced than clinical endpoints convey.

What Users Say Is Going Well

The most common positive theme is a DXA scan result that surprises users. One recurring pattern on r/osteoporosis: users who started with T-scores of -3.0 or lower at the lumbar spine report follow-up DXA results showing T-scores in the -2.0 to -2.5 range after 12 months of injections. While these are self-reports without adjudication, they are directionally consistent with FRAME, where women with baseline T-scores around -2.5 showed the most absolute BMD change. [1]

Several users describe the injection itself as manageable. The two-injection protocol per visit draws comments about the 10-to-15-second sting at each site, but most report this as minor compared with anxiety about the injections beforehand.

One practical note repeated across forums: users who scheduled their monthly appointments at the same clinic on the same day of each month had far fewer missed doses than those who rescheduled. Adherence to the full 12-dose course matters because ARCH showed that fracture benefits at 24 months depended on completing the initial romosozumab sequence before switching to alendronate. [2]

What Users Say Is Difficult

Arthralgia and musculoskeletal pain appear in roughly 10-12% of forum posts describing side effects, which mirrors the 10.7% rate of arthralgia reported in FRAME for the romosozumab arm. [1] Injection-site reactions (bruising, redness, mild swelling) are the second most common complaint.

A smaller but consistent group of users reports fatigue in the first two to three days after each injection. This is not listed among the most common adverse events in the FRAME prescribing information, but it parallels what some patients report with denosumab. [7]

The cardiovascular black-box warning generates visible anxiety in forums. The FDA added this warning after ARCH showed a numerically higher rate of serious cardiovascular events in the romosozumab arm versus alendronate in the first 12 months (2.5% vs. 1.9%). [2, 8] Users whose prescribers discussed this proactively report feeling more at ease; those who discovered the warning by reading the package insert themselves describe it as alarming. Clear prescriber communication ahead of dose one makes a measurable difference in adherence.

Hypocalcemia and Dental Concerns

Romosozumab carries a risk of hypocalcemia, particularly in patients with vitamin D deficiency. The FDA label recommends correcting hypocalcemia before initiating therapy. [8] Forum users who experienced symptomatic hypocalcemia (muscle cramps, perioral tingling) report that their prescribers had not checked 25-OH vitamin D levels before the first injection.

The osteonecrosis of the jaw (ONJ) concern raised with denosumab and bisphosphonates applies theoretically to any bone-active agent, but the incidence in FRAME was <0.1% and not statistically different from placebo. [1] Dental evaluations before starting therapy are still recommended in standard practice.

How Year-1 BMD Gains Translate to Fracture Risk Reduction

BMD alone is not a complete fracture risk predictor, but the relationship is well-established. A 10% increase in lumbar spine BMD is associated with roughly a 40-60% reduction in vertebral fracture risk based on epidemiological models. [9] The 13.3% FRAME lumbar spine gain exceeds that threshold for most patients.

The FRAME extension data (years 2 and 3) showed that patients who transitioned from romosozumab to denosumab maintained and slightly increased BMD gains. [10] Users who switched to bisphosphonates instead showed smaller continued gains, which is consistent with pharmacological differences between the two antiresorptive classes. A prescriber choosing the post-romosozumab agent should factor in individual fracture risk, renal function, and patient preference.

FRAX Score Context

FRAX (the WHO fracture risk assessment tool) does not yet incorporate BMD velocity or change over time, only point-in-time T-score values. [11] This means a FRAX score pulled immediately after 12 months of romosozumab will reflect improved T-scores but still anchors the 10-year probability calculation to the patient's age, prior fracture history, and other clinical variables. Users asking their doctors why their FRAX score did not drop as dramatically as their BMD increased are asking a valid question. The tool was not designed to capture treatment-driven change.

Who Responds Best

FRAME subgroup analyses suggest larger absolute BMD gains in patients with:

• Lower baseline T-scores (more room to improve)
• Higher baseline P1NP levels (indicating active bone formation capacity)
• Adequate baseline 25-OH vitamin D (>30 ng/mL) [1]

Patients with prior bisphosphonate use showed attenuated P1NP response to romosozumab in smaller studies, though ARCH included a meaningful proportion of bisphosphonate-naive versus previously treated women. [2]

Side Effect Profile: Trial Data vs. User Experience

Injection-Site Reactions

In FRAME, injection-site reactions occurred in 3.4% of romosozumab patients versus 2.9% placebo. [1] Forum reports skew higher, likely because users experiencing no reaction do not post about it. The practical signal from forums: reactions tend to lessen after months 3-4 once the injection sites have been rotated adequately between the abdomen, upper arm, and thigh.

Cardiovascular Risk

The ARCH trial cardiovascular signal remains the most clinically consequential concern. Patients with a prior myocardial infarction or stroke within the preceding 12 months are contraindicated per FDA labeling. [8] The Endocrine Society's 2020 clinical practice guideline on osteoporosis notes that romosozumab should be used with caution in patients with elevated baseline cardiovascular risk, and that the benefit-risk calculation favors treatment in patients with very high fracture risk who are cardiovascular-risk-eligible. [12]

As the guideline states directly: "For women with osteoporosis at very high risk of fracture, we suggest treatment with romosozumab for 12 months followed by antiresorptive therapy." [12]

Hypocalcemia Monitoring Protocol

A pre-treatment checklist drawn from the FDA label and standard endocrinology practice:

1. Serum calcium, ideally within 4 weeks of dose one [8]
2. 25-OH vitamin D, with repletion to >30 ng/mL before injection
3. Renal function panel (eGFR), as hypocalcemia risk increases with renal impairment
4. Dental evaluation if the patient has active dental disease or planned invasive procedures

Does Evenity Work for Everyone?

No single osteoporosis drug works identically in every patient. Romosozumab's BMD response is substantial in most trial participants, but roughly 10-15% of users in FRAME showed <5% lumbar spine BMD gain at 12 months. [1] Secondary causes of bone loss (hyperparathyroidism, celiac disease, glucocorticoid use) can blunt response and should be ruled out before attributing a poor result to the drug itself.

When Prescribers Consider Romosozumab First-Line

Current Endocrine Society guidance and the AACE/ACE 2020 osteoporosis guidelines both support romosozumab as a first-line option in patients classified as "very high fracture risk," defined broadly as a T-score below -3.0, a recent fragility fracture, or a 10-year major osteoporotic fracture probability above 30% on FRAX. [12, 13]

The AACE guideline states: "Anabolic therapy is preferred for patients at very high risk, as these agents produce greater BMD gains and fracture risk reduction compared with antiresorptive therapy initiated first." [13]

For patients at high (but not very high) fracture risk, bisphosphonates or denosumab remain appropriate first-line choices given their long safety track records and lower cost.

Insurance and Access Realities

Real-user forums spend considerable space on cost. Evenity's list price exceeds $1,800 per monthly dose in the United States as of 2024. Amgen's patient assistance program (Amgen SupportPlus) provides access pathways for qualifying patients, and Medicare Part B covers the injection as an administered biologic. Users who receive injections in-office under Part B consistently report better coverage experiences than those who attempt to process it under Part D as a self-administered drug.

Transitioning Off Romosozumab: What Happens After Month 12

Stopping romosozumab without immediately starting an antiresorptive leads to rapid bone loss. FRAME extension data showed that BMD declined toward baseline values within 12 months of stopping romosozumab without follow-on therapy. [10] This is not unique to romosozumab. The same rebound phenomenon occurs with denosumab, and it is particularly pronounced after anabolic agents because bone turnover rebounds sharply once the anabolic stimulus is removed. [14]

Choosing the Follow-On Agent

The evidence base most directly supports denosumab (Prolia) or zoledronic acid (Reclast) as post-romosozumab options:

• FRAME extension: romosozumab followed by denosumab produced additional BMD gains of 5.6% at the lumbar spine over 24 months post-transition. [10]
• ARCH: romosozumab followed by alendronate showed sustained fracture reduction benefit at 24-month total follow-up. [2]
• Zoledronic acid data in the post-anabolic sequence (from post-teriparatide studies) suggests comparable BMD consolidation to denosumab, though direct romosozumab-to-zoledronate RCT data are limited. [15]

Patients on denosumab post-romosozumab must not discontinue denosumab abruptly, given the risk of multiple vertebral fractures documented with denosumab discontinuation. [14]

Comparing Romosozumab to Teriparatide at 12 Months

Both romosozumab and teriparatide (Forteo) are anabolic agents, but their mechanisms and magnitudes of effect differ. The STRUCTURE trial (N=436) compared romosozumab directly to teriparatide in postmenopausal women previously treated with bisphosphonates. At 12 months, romosozumab produced significantly greater total hip BMD gains (+2.6%) versus teriparatide (-0.6%), a difference of 3.2 percentage points (P<0.0001). [16] Lumbar spine gains were similar between the two agents in STRUCTURE.

For hip fracture risk in particular, this distinction matters. Users transitioning from long-term bisphosphonate therapy who need hip-focused BMD improvement may benefit more from romosozumab than teriparatide based on these data.